CCL2 expression can increase the resistance to anti-angiogenic treatment, while the suppression of CCL2 may play an important role in increasing the efficacy of this type of therapy in GBM, by inhibiting the recruitment of CCL2-dependent macrophages [240]. This evidence concerns the gene CCL2 and glioblastoma.